Guardant Health Inc (GH) Stock Price & News

GH:NASDAQ

Guardant Health Inc

$161.41

+0.23%

(+0.37) 1D

$162.90

+0.92% (+1.49)

After hours

Closed: Sep 4, 4:00:01 PM GMT-4 · USD

All symbols

YTD

MAX

	Symbol	Price	Change	% Change

Generating top insights for GH...

Open

$160.00

High

$164.84

Low

$154.00

Mkt. cap

21.66B

Avg. vol.

2.11M

Volume

2.40M

52-wk high

$176.58

52-wk low

$53.40

EPS

-$3.50

Beta

1.57

Shares outstanding

134.20M

No. of employees

Open

$160.00

High

$164.84

Low

$154.00

Mkt. cap

21.66B

Avg. vol.

2.11M

Volume

2.40M

52-wk high

$176.58

52-wk low

$53.40

EPS

-$3.50

Beta

1.57

Shares outstanding

134.20M

No. of employees

Related stocks

News stories

From web sources and news partners

Business Wire

2 days ago

Guardant Health Announces Landmark FDA Approval of Guardant360

https://www.dars.gov.et/

2 weeks ago

Guardant (GH) EPS and Revenue: Available Metrics Are Broadly in Line for the Current Session; Market Response: Shares Close 4.30% Higher in Latest Trading - Analyst Consensus Shift

Profile

Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers. Wikipedia

About Guardant Health Inc

CEOHelmy Eltoukhy | AmirAli Talasaz

Employees2.5K

Founded2012

HeadquartersPalo Alto, California, United States

SectorHealth care provider

Websiteguardanthealth.com

Analyst ratings

Based on 19 analysts giving stock ratings to GH in the past 3 months

Strong buy

Buy

Hold

Sell

12-month forecast

Based on 19 Wall Street analysts offering 12 month price targets for GH in the last 3 months.

Highest

Current $161.41

$215.00 (+33.20%)

Average

$194.00 (+20.19%)

Lowest

$125.00 (-22.56%)

Analyst	Recommendation	Action	Price target	Projected	Date
Evie Koslosky Goldman Sachs	Buy	Maintained	$210.00	+30.1%	09/01/2026
Mark Massaro BTIG	Buy	Reiterated	$195.00	+20.8%	09/01/2026
Matt Larew William Blair	Buy	Maintained	-	-	09/01/2026
David Westenberg Piper Sandler	Buy	Maintained	$193.00	+19.6%	08/24/2026
Casey Woodring J.P. Morgan	Buy	Maintained	$195.00	+20.8%	08/04/2026
Bradley Bowers Mizuho Securities	Buy	Maintained	$200.00	+23.9%	08/04/2026
Mason Carrico Stephens	Buy	Maintained	$195.00	+20.8%	08/04/2026
Kallum Titchmarsh Morgan Stanley	Buy	Reiterated	$185.00	+14.6%	08/04/2026
Kyle Mikson CFA Canaccord Genuity	Buy	Maintained	$205.00	+27%	08/02/2026
Daniel Arias Stifel Nicolaus	Buy	Maintained	$180.00	+11.5%	08/03/2026
Michael Ryskin Bank of America Securities	Buy	Maintained	-	-	07/31/2026
Dan Leonard RBC Capital	Buy	Reiterated	$200.00	+23.9%	07/31/2026
Luke Sergott Barclays	Buy	Maintained	$200.00	+23.9%	07/31/2026
Daniel Brennan TD Cowen	Buy	Reiterated	$210.00	+30.1%	07/31/2026
Subbu Nambi Guggenheim	Buy	Reiterated	$190.00	+17.7%	07/31/2026
Brandon Couillard Wells Fargo	Buy	Maintained	$125.00	-22.6%	07/29/2026
Eve Burstein Bernstein	Buy	Maintained	$200.00	+23.9%	07/22/2026
Patrick B Donnelly Citi	Buy	Maintained	$215.00	+33.2%	07/08/2026
Vijay Kumar Evercore ISI	Buy	Maintained	$200.00	+23.9%	07/06/2026
Puneet Souda Leerink Partners	Buy	Reiterated	-	-	06/02/2026
Paige Chamberlain‏ Wolfe Research	Buy	Reiterated	$150.00	-7.1%	06/01/2026
Unknown Analyst Wolfe Research	Buy	Reiterated	$150.00	-7.1%	06/01/2026
Andrew Brackmann William Blair	Buy	Maintained	-	-	05/27/2026
Catherine Ramsey Schulte Robert W. Baird	Buy	Maintained	$129.00	-20.1%	05/08/2026
Andrew Cooper Raymond James	Buy	Reiterated	$129.00	-20.1%	02/23/2026
William Bonello Craig-Hallum	Buy	Reiterated	$125.00	-22.6%	02/20/2026

All values in USD	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	265.20M	281.27M	301.66M	334.98M
Cost of goods sold	93.59M	99.49M	104.92M	115.95M
Cost of revenue	93.59M	99.49M	104.92M	115.95M
Research and development expenses	89.96M	98.26M	91.04M	96.53M
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	180.53M	204.20M	227.06M	250.61M
Operating expense	270.48M	302.46M	318.10M	347.15M
Total operating expenses	364.07M	401.96M	423.02M	463.10M
Operating income	-98.87M	-120.69M	-121.35M	-128.12M
Other non operating income	-48.00K	-4.69M	1.55M	308.00K
EBT including unusual items	-92.59M	-130.22M	-111.70M	-119.96M
EBT excluding unusual items	-92.47M	-116.52M	-111.70M	-118.96M
Income tax expense	136.00K	-1.73M	372.00K	185.00K
Effective tax rate	-0.15%	1.33%	-0.33%	-0.15%
Other operating expenses	-	-	-	-
Net income	-92.72M	-128.49M	-112.08M	-120.14M
Net profit margin	-34.96%	-45.68%	-37.15%	-35.87%
Earnings per share	-0.39	-0.50	-0.45	-0.42
Interest and investment income	7.39M	10.03M	11.15M	10.20M
Interest expense	-943.00K	-1.18M	-3.05M	-1.35M
Net interest expenses	6.45M	8.85M	8.10M	8.85M
Depreciation and amortization charges	-	-	-	-
EBITDA	-89.47M	-110.64M	-111.91M	-118.56M
Gain or loss from assets sale	-	-	-	-

Finance

Ask anything